International Journal of Clinical Research

Objective To explore the clinical effect of sex hormone drugs on adolescent patients with abnormal uterine bleeding. Methods The samples provided by the department of Obstetrics and Gynecology of the investigator hospital was selected to study a total of 100 adolescent patients with abnormal uterine bleeding, enrolled from January 2023 to January 2024. Randomized into 2 groups, numerical table method. The control group was treated with estrogen alone, while the observation group was combined with compound short-acting oral contraceptives. Treatment effects, improvement in bleeding, incidence of adverse reactions, and sex hormone levels before and after treatment were compared between the two groups. Results The response rate of the observation group was 100.00%, higher than that of the control group (χ2=4.1667; P<0.05）。The bleeding control time in the observation group (1.12±0.46) d, complete hemostasis (2.12±0.74) d was shorter than the control group (110.12±10.12) mL less than the control group (T=7.2635; T=7.0935; T=6.7894; P <0.05). The incidence of adverse reactions in the observation group was 8.00% slightly higher than that in the control group, but the difference was compared (χ2=0.1536; P>0.05）。E2 was (240.12±21.36) pmol/L, FSH (5.32±0.72) IU / L, and LH (3.25 ± 0.66) IU / L, and P (2.23 ± 0.66) nmol / L, lower than the control group (T=8.5084; T=15.7610; T=12.4819; T=8.1807; P <0.05). Conclusion In the treatment of abnormal uterine bleeding in puberty, sex hormone drugs have ideal efficacy, which can improve the sex hormone level of patients, and control the bleeding quickly, and the treatment safety is high, which is worth popularizing.

Abnormal uterine bleeding in puberty; Sex hormone drugs; Therapeutic effect; Adverse reaction; Sex hormone level